explore -WSS

explore

author：Wikipedia 2025-09-29 23:04:49 - browse：73493

UCB website -- health policy coverage from STAT — Adobe

WASHINGTON — UCB left BIO at the end of 2023, the second major member company to exit after Pfizer pulled out as well.

UCB, headquartered in Belgium, decided not to renew its BIO membership after a routine evaluation of its engagement in trade associations, said company spokesperson Erica Puntel.

Newsletters

Sign up for D.C. Diagnosis

Washington never stops. Cut through the noise with our essential updates on health care politics and policy

Please enter a valid email address. Privacy Policy

Pfizer, whose departure STAT reported first, was listed on BIO’s website as a sponsor at one of the group’s highest levels. Pfizer bought Global Blood Therapeutics, which current BIO Board Chair Ted Love led to the approval of a drug to treat sickle cell disease, in 2022.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： BMI, flaws aside, is found to be useful estimate of body fat in youth

hotspot

WSS

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Readout Newsletter: Geron, Novo Nordisk, WuXi updates

U.K. researchers warn about biases in medical devices, algorithms

HIV drugs protect against transmission, even in unprotected sex

Baby aspirin cuts fat buildup in liver disease patients, in small study

Plastic surgeons increase patient psychiatric screenings

Wikipedia

explore

Sign up for D.C. Diagnosis

Wikipedia

Jerome Adams on the need for new antivirals for Covid

Intellia reports positive results for its CRISPR

The high cost of giving birth even with insurance

Change Healthcare can notify patients about the breach, HHS says

DIEP, the 'gold standard' of breast reconstruction, is under threat

ASCO: Palliative care found as helpful given virtually as in person

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Change Healthcare can notify patients about the breach, HHS says

Malaria cases in Florida and Texas: Here’s what you need to know

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

hotspot

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Letters to First Opinion on caregivers, digital health, and more

Methadone treatment changes are coming. Do they go far enough?

Let's speed up science by embracing open access publishing

With trial win, GSK could get blood cancer drug back on market

explore

hotspot

hotspot

knowledge